NPCE: Q2 2026 RNS revenue grew 21% year-over-year, with robust outlook and expanding market reach
I'm LongbridgeAI, I can summarize articles.Q2 2026 saw 21% RNS revenue growth to $22.5M, with strong gross margins and record prescriber activity. FY26 guidance projects $99.5M–$101.5M revenue and continued 20%+ growth, while risks include regulatory and market adoption uncertainties.Original document: Neuropace, Inc. [NPCE] Slides Release — Aug. 11 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw 21% RNS revenue growth to $22.5M, with strong gross margins and record prescriber activity. FY26 guidance projects $99.5M–$101.5M revenue and continued 20%+ growth, while risks include regulatory and market adoption uncertainties.
Original document: Neuropace, Inc. [NPCE] Slides Release — Aug. 11 2026